CoChat

TNF-α Signals Through PKCζ/NF-κB to Alter the Tight Junction Complex and Increase Retinal Endothelial Cell Permeability

Open access

The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Tumor necrosis factor-α (TNF-α) and interleukin-1 beta (IL-1β) are elevated in the vitreous of diabetic patients and in retinas of diabetic rats associated with increased retinal vascular permeability. However, the molecular mechanisms underlying retinal vascular permeability induced by these cytokines are poorly understood. In this study, the effects of IL-1β and TNF-α on retinal endothelial cell permeability were compared and the molecular mechanisms by which TNF-α increases cell permeability were elucidated. RESEARCH DESIGN AND METHODS: Cytokine-induced retinal vascular permeability was measured in bovine retinal endothelial cells (BRECs) and rat retinas. Western blotting, quantitative real-time PCR, and immunocytochemistry were performed to determine tight junction protein expression and localization. RESULTS: IL-1β and TNF-α increased BREC permeability, and TNF-α was more potent. TNF-α decreased the protein and mRNA content of the tight junction proteins ZO-1 and claudin-5 and altered the cellular localization of these tight junction proteins. Dexamethasone prevented TNF-α–induced cell permeability through glucocorticoid receptor transactivation and nuclear factor-kappaB (NF-κB) transrepression. Preventing NF-κB activation with an inhibitor κB kinase (IKK) chemical inhibitor or adenoviral overexpression of inhibitor κB alpha (IκBα) reduced TNF-α–stimulated permeability. Finally, inhibiting protein kinase C zeta (PKCζ) using both a peptide and a novel chemical inhibitor reduced NF-κB activation and completely prevented the alterations in the tight junction complex and cell permeability induced by TNF-α in cell culture and rat retinas. CONCLUSIONS: These results suggest that PKCζ may provide a specific therapeutic target for the prevention of vascular permeability in retinal diseases characterized by elevated TNF-α, including diabetic retinopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-1606

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. IL-1β and TNF-α increase retinal endothelial cell permeability. A–D: BRECs were grown to confluence on transwell filters and then exposed to IL-1β or TNF-α in a concentration- and time-dependent manner. The monolayer permeability to 70 kDa dextran was measured as described in research design and methods. A: Cells were treated with 1, 10, and 100 ng/ml IL-1β for 24 h. B: Cells were treated with 10 ng/ml IL-1β for 0.5, 6, and 24 h. C: Cells were treated with 1, 2.5, 5, and 10 ng/ml TNF-α for 6 h. D: Cells were treated with 5 ng/ml TNF-α for 0.5, 6, and 24 h. E and F: IL-1β and TNF-α effect on cell viability. BRECs were treated with 10 ng/ml IL-1β or 5 ng/ml TNF-α for 6 and 24 h. E: Relative cell viability was measured by calcein AM cleavage by live cells. F: Retinal endothelial cell apoptosis was evaluated by caspase-3/7 activation. As a positive control of apoptosis induction, cells were treated with 100 nmol/l staurosporine (STP) for 6 h. The results represent the mean ± SEM of at least four independent experiments and are expressed relative to control (Ctrl). **P < 0.01, significantly different from control as determined by ANOVA followed by Dunnett post hoc test.
FIG. 1. IL-1β and TNF-α increase retinal endothelial cell permeability. A–D: BRECs were grown to confluence on transwell filters and then exposed to IL-1β or TNF-α in a concentration- and time-dependent manner. The monolayer permeability to 70 kDa dextran was measured as described in research design and methods. A: Cells were treated with 1, 10, and 100 ng/ml IL-1β for 24 h. B: Cells were treated with 10 ng/ml IL-1β for 0.5, 6, and 24 h. C: Cells were treated with 1, 2.5, 5, and 10 ng/ml TNF-α for 6 h. D: Cells were treated with 5 ng/ml TNF-α for 0.5, 6, and 24 h. E and F: IL-1β and TNF-α effect on cell viability. BRECs were treated with 10 ng/ml IL-1β or 5 ng/ml TNF-α for 6 and 24 h. E: Relative cell viability was measured by calcein AM cleavage by live cells. F: Retinal endothelial cell apoptosis was evaluated by caspase-3/7 activation. As a positive control of apoptosis induction, cells were treated with 100 nmol/l staurosporine (STP) for 6 h. The results represent the mean ± SEM of at least four independent experiments and are expressed relative to control (Ctrl). **P < 0.01, significantly different from control as determined by ANOVA followed by Dunnett post hoc test.CC BY-NC-ND · PubMed Central
FIG. 2. TNF-α alters tight junction proteins content and cell localization. BRECs were treated with 5 ng/ml TNF-α for 0.5 and 6 h. Whole-cell extracts were assayed for ZO-1 (A), claudin-5 (B), and occludin (C) immunoreactivity by Western blotting. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least five independent experiments and are expressed as the relative amount compared with control (Ctrl). *P < 0.05, **P < 0.01, significantly different from control as determined by ANOVA followed by Dunnett post hoc test. Total RNA was isolated after 6 h of TNF-α treatment, and the transcript levels of ZO-1 (D), claudin-5 (E), and occludin (F) were analyzed by qPCR. Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control. Results represent the mean ± SEM of eight independent experiments and are expressed as the relative amount compared with control conditions. *P < 0.05, ***P < 0.001, significantly different from control as determined by Student t test. G: Cells were immunolabeled for ZO-1, claudin-5, and occludin 6 h after TNF-α treatment, and 10 confocal Z-stacks were taken through 2.56 μm and projected into one image. Arrows indicate continuous staining at cell borders. These results are representative of four independent experiments. Scale bar, 25 μm.
FIG. 2. TNF-α alters tight junction proteins content and cell localization. BRECs were treated with 5 ng/ml TNF-α for 0.5 and 6 h. Whole-cell extracts were assayed for ZO-1 (A), claudin-5 (B), and occludin (C) immunoreactivity by Western blotting. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least five independent experiments and are expressed as the relative amount compared with control (Ctrl). *P < 0.05, **P < 0.01, significantly different from control as determined by ANOVA followed by Dunnett post hoc test. Total RNA was isolated after 6 h of TNF-α treatment, and the transcript levels of ZO-1 (D), claudin-5 (E), and occludin (F) were analyzed by qPCR. Glyceraldehyde-3-phosphate dehydrogenase was used as an endogenous control. Results represent the mean ± SEM of eight independent experiments and are expressed as the relative amount compared with control conditions. *P < 0.05, ***P < 0.001, significantly different from control as determined by Student t test. G: Cells were immunolabeled for ZO-1, claudin-5, and occludin 6 h after TNF-α treatment, and 10 confocal Z-stacks were taken through 2.56 μm and projected into one image. Arrows indicate continuous staining at cell borders. These results are representative of four independent experiments. Scale bar, 25 μm.CC BY-NC-ND · PubMed Central
FIG. 3. Dexamethasone prevents TNF-α–induced cell permeability through transactivation of the glucocorticoid receptor. A: BRECs were grown to confluence on transwell filters and treated with 50 ng/ml dexamethasone (Dex) 18 h before TNF-α treatment (5 ng/ml, 6 h). B: Cells were treated with 5 μmol/l RU486 1 h before Dex treatment. The monolayer permeability to 70 kDa dextran was measured as described in research design and methods. The results represent the mean ± SEM of at least seven independent experiments and are expressed relative to control (Ctrl). *P < 0.05, ***P < 0.001, significantly different as determined by ANOVA followed by Bonferroni post hoc test.
FIG. 3. Dexamethasone prevents TNF-α–induced cell permeability through transactivation of the glucocorticoid receptor. A: BRECs were grown to confluence on transwell filters and treated with 50 ng/ml dexamethasone (Dex) 18 h before TNF-α treatment (5 ng/ml, 6 h). B: Cells were treated with 5 μmol/l RU486 1 h before Dex treatment. The monolayer permeability to 70 kDa dextran was measured as described in research design and methods. The results represent the mean ± SEM of at least seven independent experiments and are expressed relative to control (Ctrl). *P < 0.05, ***P < 0.001, significantly different as determined by ANOVA followed by Bonferroni post hoc test.CC BY-NC-ND · PubMed Central
FIG. 4. Dexamethasone prevents TNF-α–induced alterations in the tight junction complex. Confluent BRECs were treated with 50 ng/ml Dex 18 h before TNF-α treatment (5 ng/ml, 6 h). Whole-cell extracts were assayed for (A) ZO-1, (B) claudin-5, and (C) occludin immunoreactivity by Western blotting as described in research design and methods. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least five independent experiments and are expressed as the relative amount compared with control. *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test. D: Cells were immunolabeled for ZO-1, claudin-5, and occludin and 10 confocal Z-stacks were taken through 2.56 μm and projected into one image. These results are representative of four independent experiments. Scale bar, 25 μm.
FIG. 4. Dexamethasone prevents TNF-α–induced alterations in the tight junction complex. Confluent BRECs were treated with 50 ng/ml Dex 18 h before TNF-α treatment (5 ng/ml, 6 h). Whole-cell extracts were assayed for (A) ZO-1, (B) claudin-5, and (C) occludin immunoreactivity by Western blotting as described in research design and methods. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least five independent experiments and are expressed as the relative amount compared with control. *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test. D: Cells were immunolabeled for ZO-1, claudin-5, and occludin and 10 confocal Z-stacks were taken through 2.56 μm and projected into one image. These results are representative of four independent experiments. Scale bar, 25 μm.CC BY-NC-ND · PubMed Central
FIG. 5. Effect of NF-κB inhibition on TNF-α–induced cell permeability. A: Cells were incubated with 1 μmol/l IKK VII, 30 min before the addition of 5 ng/ml TNF-α for 5 min. Whole-cell lysates were assayed for phophorylated IκBα (Ser32/Ser36) and total IκBα immunoreactivity by Western blotting. B: Cells were grown to confluence on transwell filters and then treated with 1 μmol/l IKK VII 30 min before TNF-α addition (5 ng/ml, 6 h). The monolayer permeability to 70 kDa dextran was measured as described. C–E: Adenovirus-mediated overexpression of IκBα. BRECs were transduced with AdEmpty or AdIκBα as described. C: Whole lysates of BRECs were used to detect IκBα, GFP, and β-actin (loading control) by Western blotting. D: After 28 h of adenovirus transduction, cells were exposed to 5 ng/ml TNF-α for 2 h. Total RNA was isolated, and the transcript levels of IL-8 were analyzed by qPCR. E: Cells were grown to confluence on transwell filters and after 24 h of adenovirus transduction cells were treated with 5 ng/ml TNF-α for 6 h. The monolayer permeability to 70 kDa dextran was measured. The results represent the mean ± SEM of at least three independent experiments and are expressed relative to control (Ctrl). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different as determined by ANOVA followed by Bonferroni post hoc test.
FIG. 5. Effect of NF-κB inhibition on TNF-α–induced cell permeability. A: Cells were incubated with 1 μmol/l IKK VII, 30 min before the addition of 5 ng/ml TNF-α for 5 min. Whole-cell lysates were assayed for phophorylated IκBα (Ser32/Ser36) and total IκBα immunoreactivity by Western blotting. B: Cells were grown to confluence on transwell filters and then treated with 1 μmol/l IKK VII 30 min before TNF-α addition (5 ng/ml, 6 h). The monolayer permeability to 70 kDa dextran was measured as described. C–E: Adenovirus-mediated overexpression of IκBα. BRECs were transduced with AdEmpty or AdIκBα as described. C: Whole lysates of BRECs were used to detect IκBα, GFP, and β-actin (loading control) by Western blotting. D: After 28 h of adenovirus transduction, cells were exposed to 5 ng/ml TNF-α for 2 h. Total RNA was isolated, and the transcript levels of IL-8 were analyzed by qPCR. E: Cells were grown to confluence on transwell filters and after 24 h of adenovirus transduction cells were treated with 5 ng/ml TNF-α for 6 h. The monolayer permeability to 70 kDa dextran was measured. The results represent the mean ± SEM of at least three independent experiments and are expressed relative to control (Ctrl). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different as determined by ANOVA followed by Bonferroni post hoc test.CC BY-NC-ND · PubMed Central
FIG. 6. Inhibition of PKCζ inhibits NF-κB activation by TNF-α. A: BRECs were treated with 10 μmol/l PKCζI-1, a PKCζ inhibitor, 30 min before the addition of 5 ng/ml TNF-α for 2 h. Total RNA was isolated, and the transcript levels of IL-8 were analyzed by qPCR. The results represent the mean ± SEM of six independent experiments and are expressed relative to control (Ctrl). B: 293T-NF-kB-luc cells, with a κB-dependent luciferase reporter gene, were treated with 10 or 50 μmol/l PKCζI-1 30 min prior to the addition of TNF-α for 6 h. Cells were harvested, and luciferase activity was determined in whole-cell lysates. The results represent the mean ± SEM of four independent experiments and are expressed relative to TNF-α. ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test.
FIG. 6. Inhibition of PKCζ inhibits NF-κB activation by TNF-α. A: BRECs were treated with 10 μmol/l PKCζI-1, a PKCζ inhibitor, 30 min before the addition of 5 ng/ml TNF-α for 2 h. Total RNA was isolated, and the transcript levels of IL-8 were analyzed by qPCR. The results represent the mean ± SEM of six independent experiments and are expressed relative to control (Ctrl). B: 293T-NF-kB-luc cells, with a κB-dependent luciferase reporter gene, were treated with 10 or 50 μmol/l PKCζI-1 30 min prior to the addition of TNF-α for 6 h. Cells were harvested, and luciferase activity was determined in whole-cell lysates. The results represent the mean ± SEM of four independent experiments and are expressed relative to TNF-α. ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test.CC BY-NC-ND · PubMed Central
FIG. 7. TNF-α increases cell permeability in a PKCζ-dependent manner. BRECs were grown to confluence on transwell filters and then treated with (A) 2 μmol/l LY294002 (LY), (B) 10 μmol/l PKCζI-1, and (C) 250 nmol/l PKCζ pseudosubstrate inhibitor (PKCζp). The monolayer permeability to 70 kDa dextran was measured as described. Results represent the mean ± SEM of at least five experiments and are expressed relative to Ctrl. D–F: PKCζI-1 prevents tight junction complex disruption induced by TNF-α. Whole-cell extracts were assayed for (D) ZO-1, (E) claudin-5, and (F) occludin immunoreactivity by Western blotting. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least eight independent experiments and are expressed as the relative amount compared with control (Ctrl). All inhibitors were added to the cell culture medium 30 min before TNF-α addition (5 ng/ml, 6 h). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different form TNF-α, as determined by ANOVA followed by Bonferroni post hoc test.
FIG. 7. TNF-α increases cell permeability in a PKCζ-dependent manner. BRECs were grown to confluence on transwell filters and then treated with (A) 2 μmol/l LY294002 (LY), (B) 10 μmol/l PKCζI-1, and (C) 250 nmol/l PKCζ pseudosubstrate inhibitor (PKCζp). The monolayer permeability to 70 kDa dextran was measured as described. Results represent the mean ± SEM of at least five experiments and are expressed relative to Ctrl. D–F: PKCζI-1 prevents tight junction complex disruption induced by TNF-α. Whole-cell extracts were assayed for (D) ZO-1, (E) claudin-5, and (F) occludin immunoreactivity by Western blotting. Representative Western blots for each tight junction protein and β-actin (loading control) are presented above each respective graph. The results are normalized to β-actin and represent the mean ± SEM of at least eight independent experiments and are expressed as the relative amount compared with control (Ctrl). All inhibitors were added to the cell culture medium 30 min before TNF-α addition (5 ng/ml, 6 h). *P < 0.05, **P < 0.01, ***P < 0.001, significantly different from control; #P < 0.05, ##P < 0.01, ###P < 0.001, significantly different form TNF-α, as determined by ANOVA followed by Bonferroni post hoc test.CC BY-NC-ND · PubMed Central
FIG. 8. PKCζI-1 prevents TNF-α–induced retinal vascular permeability in vivo. Animals' eyes were injected with PBS with 0.1% BSA, TNF-α (10 ng); PKCζI-1 (280 ng); or with both PKCζI-1 and TNF-α. A: Evans blue leakage was evaluated 24 h after intravitreous injections. The results represent the mean ± SEM (n = 7–8 animals per group) and are expressed relative to control (Ctrl; PBS-injected eyes). **P < 0.01, significantly different from control; ##P < 0.01, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test. B: PKCζI-1 prevents the alterations in tight junction proteins induced by TNF-α in vivo. Whole retinas were immunolabeled for ZO-1 and occludin 4 h after injection. Images were obtained on a Leica TCS SP2 AOBS confocal microscope and are presented as a maximum projection. Arrows indicate loss and/or discontinuous cell border staining. Scale bar, 25 μm. (A high-quality digital representation of this figure is available in the online issue.)
FIG. 8. PKCζI-1 prevents TNF-α–induced retinal vascular permeability in vivo. Animals' eyes were injected with PBS with 0.1% BSA, TNF-α (10 ng); PKCζI-1 (280 ng); or with both PKCζI-1 and TNF-α. A: Evans blue leakage was evaluated 24 h after intravitreous injections. The results represent the mean ± SEM (n = 7–8 animals per group) and are expressed relative to control (Ctrl; PBS-injected eyes). **P < 0.01, significantly different from control; ##P < 0.01, significantly different from TNF-α, as determined by ANOVA followed by Bonferroni post hoc test. B: PKCζI-1 prevents the alterations in tight junction proteins induced by TNF-α in vivo. Whole retinas were immunolabeled for ZO-1 and occludin 4 h after injection. Images were obtained on a Leica TCS SP2 AOBS confocal microscope and are presented as a maximum projection. Arrows indicate loss and/or discontinuous cell border staining. Scale bar, 25 μm. (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

Items 201–300 of 410

Metadata

Authors
Aveleira, C. A., Lin, C.-M., Abcouwer, S. F., Ambrósio, A. F., & Antonetti, D. A.
Affiliations
  • Pennsylvania State University (US)
  • Centro de Neurociências e Biologia Celular (PT)
Corresponding author
Aveleira, Célia A.
Venue
Diabetes
Published
2010-08-06
Volume
59
Issue
11
Pages
2872-2882
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2155144135
Cited by
403
References
57
Citations by year
2026: 18 · 2025: 25 · 2024: 17 · 2023: 26 · 2022: 31 · 2021: 33 · 2020: 34 · 2019: 35 · 2018: 35 · 2017: 31 · 2016: 23 · 2015: 29 · 2014: 17 · 2013: 21 · 2012: 20
FWCI
9.44
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Juvenile Diabetes Research Foundation International
  • University of Pennsylvania
  • Pennsylvania State University
  • National Institutes of Health (012021)
  • Penn State College of Medicine
  • National Eye Institute (R01EY012021, R01EY016413)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
TNF-α, IL-1β, tight junction proteins, ZO-1, claudin-5, protein kinase C, NF-κB signaling, dexamethasone, glucocorticoid receptor, IκBα, diabetic retinopathy, retinal vascular permeability, IKK inhibitor
MeSH terms
Protein Kinase C zeta, Animals, Cattle, Cell Membrane Permeability, Dexamethasone, Diabetic Retinopathy, Humans, Male, Permeability, Protein Kinase C, Retina, Retinal Diseases, Tumor Necrosis Factor-alpha, NF-kappa B, Rats, Sprague-Dawley, Tight Junctions, Endothelial Cells, Rats, Interleukin-1beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.